Elucidata Corporation and Auron Therapeutics have announced a strategic scientific collaboration aimed at identifying and validating therapeutic targets for Acute Myeloid Leukemia (AML) and eight other oncology indications. This four-year partnership brings together Elucidata’s data-centric AI capabilities and Auron’s differentiation-based approach to cancer treatment, with the goal of advancing more precise and effective approach to cancer treatment.

As part of the collaboration, Elucidata will leverage its data-centric AI platform, Polly, to analyze large-scale transcriptomic, metabolomic, and epigenetic data from biological samples, alongside disease and treatment response data from patients. This effort represents one of the broadest applications of differentiation-based therapy in oncology  and has the potential to significantly improve clinical outcomes for cancer patients

Polly integrates multiple forms of omics data using advanced computational methods to characterize healthy and diseased states at the molecular level.  Auron is contributing phenotypic data along with transcriptomic, metabolomic, and epigenetic data from hundreds of patient samples. Together, these analyses will help identify and validate targets for developing new therapies with improved efficacy and fewer side effects for specific patient subgroups. The insights from this work will also enable better stratification of cancer subtypes.

About Auron Therapeutics

Auron Therapeutics was founded in 2018 to develop therapies that cure cancer by changing the paradigm from cell killing to transforming malignant cells into normal cells. This approach, called differentiation therapy, reactivates cellular programs to drive tumor cell maturation and convert cancer into normal tissue. Its platforms integrate large-omic datasets with miniaturized high-throughput flow cytometry to rapidly identify and validate targets and drugs in primary human patient samples.

About Elucidata Corporation

Founded in 2015, Elucidata is transforming how biological data drives R&D decisions in both academia and industry. Elucidata's cloud based platform Polly optimizes data quality for pre-clinical and clinical drug discovery by harmonizing multi-omics and assay data into ML-ready formats. The platform's harmonization engine is operated by trained experts who curate diverse data types, annotate metadata, and ensure consistent processing at scale.

Polly accommodates more than 25 R&D data types, supporting teams across pre-clinical drug discovery and diagnostics R&D. The platform is trusted by over 25 research organizations, including four of the top ten pharmaceutical companies, to accelerate their discovery programs, and has contributed to more than 40 therapies progressing toward FDA approval. Elucidata has offices in Cambridge, MA, and New Delhi, India.

‍